ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2369

Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial

Alain Saraux1, Christophe Hudry2, Elena Zinovieva3, Agnès Courbeyrette4 and Hélène Herman-Demars3, 1Rheumatology, CHU Brest, Brest, France, 2AP-HP Hôpital Cochin, Paris, France, 3Medical Department Nordic Pharma, Paris, France, 4Medical Departement, Nordic Pharma, Paris, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Compliance, methotrexate (MTX), patient outcomes, physical function and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens. SELFi trial intended to compare historical MTX prefilled syringes vs a new MTX autoinjector in terms of treatment adherence, functional capacity, and patients’ preference at 6 months in RA patients.

Methods: SELFi was a phase III, randomized open-label trial, conducted in France between Sept. 2015 and March 2017. It included RA patients, treated by oral or injectable MTX for ≥3 months in monotherapy or in association. Patients were randomized in two arms: MTX in prefilled syringes (PS) or MTX in autoinjectors (AI) at the dosage decided by the investigator. Primary co-criteria of the study were non-inferiority of AI vs PS in terms of patients’ compliance (measured by the investigator at each visit) and functional capacity (HAQ-DI) at 6 months. Secondary criteria included patients’ satisfaction and preference.

Results: Between Sept. 2015 and Sept. 2016, 50 rheumatologists, mostly with private practice, included 271 patients, 197 of which composed the per protocol population. Patients baseline characteristics were [mean (±SD)]: age: 59.2 (±12.3) yrs; BMI: 26.0 (±4.9) kg/m²; RA duration: 5.35 (±6.70) yrs; DAS28: 3.1 (±1.2); HAQ-DI: 0.6 (±0.6). All patients were treated by MTX (1/3 oral; 2/3 parenteral) at a mean dose of 15.4 (±4.1). There were no significant differences at baseline between PS and AI arms. Proportion of good compliers (>80%) was 89.9% vs 94.9% (AI vs PS): -5% [CI 95% -18.9%; 8.9%]. HAQ decreased by a mean of 0.06 in both groups. Percentage of change was 21.3% vs 22.4% (AI vs PS): -1.1% [-35.0%; 32.7%]. Due to the high data variability, the non-inferiority could not be proved in strict sense, but differences did not appear as relevant.

Patients’ reported satisfaction (Likert Scale) secondary criteria

Easy to use

Pleasant

Satisfying

Motivating for further utilization

Reassuring

Not constraining

Not stressful

Not painful

AI / PS

AI / PS

AI / PS

AI / PS

AI / PS

AI / PS

AI / PS

AI / PS

Strongly agree

60% / 21%

7% / 0%

63% / 21%

61% / 35%

30% / 14%

51% / 36%

55% / 41%

51% / 38%

Agree

32% / 42%

20% / 11%

31% / 50%

23% / 34%

52% / 60%

18% / 17%

23% / 26%

21% / 31%

Neither agree nor disagree

4% / 23%

32% / 26%

2% / 19%

9% / 17%

9% / 15%

19% / 24%

14% / 17%

25% / 24%

Disagree

1% / 6%

26% / 30%

2% / 6%

6% / 10%

4% / 5%

10% / 15%

4% / 8%

1% / 6%

Strongly disagree

4% / 8%

14% / 33%

1% / 4%

1% / 4%

5% / 6%

2% / 8%

8% / 9%

1% / 1%

Significance level

p < 0.001

p < 0.001

p < 0.001

p = 0.001

p = 0.02

p = 0.02

p = 0.05

p = 0.15

Patients’ reported satisfaction was very significantly higher (p≤0.001) in AI arm vs PS for the following criteria: easy to use, pleasant, satisfying, willingness for further utilization and significantly higher (p<0,05) for reassuring and not constraining. Of the 132 patients who could try the both devices (during the study or in previous experiences), 127 (96%; p<0.001) preferred the autoinjector over the historical prefilled syringe. No unexpected safety issues were observed during this trial and injection point safety tolerance satisfaction was higher for AI vs PS.

Conclusion:

SELFi trial showed that although the non-inferiority of the new MTX autoinjector vs the historical prefilled-syringe was not proved in strict statistical sense, they seem comparable in terms of treatment compliance and functional capacity improvement. Besides the pen is significantly superior in terms of patients’ satisfaction and more than 95% of patients who have tried both devices declare preferring it over the syringe.


Disclosure: A. Saraux, Nordic Pharma, 5; C. Hudry, Nordic Pharma, 5; E. Zinovieva, Nordic Pharma, 3; A. Courbeyrette, Nordic Pharma, 3; H. Herman-Demars, Nordic Pharma, 3.

To cite this abstract in AMA style:

Saraux A, Hudry C, Zinovieva E, Courbeyrette A, Herman-Demars H. Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/patients-preference-goes-to-mtx-autoinjectors-over-prefilled-syringes-results-from-a-phase-iii-trial/. Accessed January 15, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-preference-goes-to-mtx-autoinjectors-over-prefilled-syringes-results-from-a-phase-iii-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.